Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Proqr Therapeutics (NQ: PRQR )

3.620 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 3.620
Bid (Size) 3.600 (28)
Ask (Size) 4.100 (10)
Prev. Close 3.620
Today's Range 3.620 - 3.620
52wk Range 1.180 - 4.620
Shares Outstanding 80,817,079
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Neurogene, Nvidia And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
ProQR Announces Third Quarter 2024 Operating and Financial Results
From ProQR Therapeutics N.V.
Via GlobeNewswire

Performance

YTD
+74.46%
+74.46%
1 Month
+4.62%
+4.62%
3 Month
+75.73%
+75.73%
6 Month
+96.74%
+96.74%
1 Year
+168.15%
+168.15%

More News

Read More
This First Solar Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Via Benzinga
ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement
From ProQR Therapeutics N.V.
Via GlobeNewswire
ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement
From ProQR Therapeutics N.V.
Via GlobeNewswire
ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares
From ProQR Therapeutics N.V.
Via GlobeNewswire
CSX Posts Weak Earnings, Joins Lucid Group, Nokia And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Why TSMC Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
Via Benzinga
ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society
From ProQR Therapeutics N.V.
Via GlobeNewswire
ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare Conference
From ProQR Therapeutics N.V.
Via GlobeNewswire
PRQR Stock Earnings: ProQR Therapeutics Beats EPS, Misses Revenue for Q2 2024
Via InvestorPlace
ProQR Announces Second Quarter 2024 Operating and Financial Results
From ProQR Therapeutics N.V.
Via GlobeNewswire
ProQR Announces Presentation on its Axiomer™ RNA Editing Technology at RNA Editing Summit
From ProQR Therapeutics N.V.
Via GlobeNewswire
ProQR Announces First Quarter 2024 Operating and Financial Results
From ProQR Therapeutics N.V.
Via GlobeNewswire
ProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer™ RNA Editing Program Targeting NTCP for Cholestatic Diseases
From ProQR Therapeutics N.V.
Via GlobeNewswire
ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024
From ProQR Therapeutics N.V.
Via GlobeNewswire
ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting
From ProQR Therapeutics N.V.
Via GlobeNewswire
ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio
From ProQR Therapeutics N.V.
Via GlobeNewswire
ProQR Announces Year End 2023 Operating and Financial Results
From ProQR Therapeutics N.V.
Via GlobeNewswire
ProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing
From ProQR Therapeutics N.V.
Via GlobeNewswire
ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024
From ProQR Therapeutics N.V.
Via GlobeNewswire
Why KeyCorp Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Why Airspan Networks Shares Are Trading Higher By Over 380%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration
From ProQR Therapeutics N.V.
Via GlobeNewswire
ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets
From ProQR Therapeutics N.V.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.